A61P 3 - Drugs for disorders of the metabolism

Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
10/2002
10/16/2002	EP1248517A2 Clonal propagation of primate offspring by embryo splitting
10/16/2002	EP1140065A4 Use of gamma-tocopherol and its oxidative metabolite llu-alpha in the treatment of disease
10/16/2002	EP0927161B1 Substituted cyclic amine metalloprotease inhibitors
10/16/2002	CN1374968A 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, method fo r producing the same, medicaments containing these compounds and their use
10/16/2002	CN1374966A 嘌呤衍生物 Purine derivatives
10/16/2002	CN1374961A Azepinoindole derivatives, the production and use thereof
10/16/2002	CN1374960A Novel integrain receptor antagonists
10/16/2002	CN1374955A Oxa-and thiazole derivatives useful as antidiabetic and antibesity agents
10/16/2002	CN1374950A Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
10/16/2002	CN1374940A O-Anisamide derivatives
10/16/2002	CN1374863A Bicyclic antagonists selective for the alpha beta integrin
10/16/2002	CN1374859A 药物粉剂 Drug powder
10/16/2002	CN1374839A Potassium calcium citrate compositions and methods for production
10/16/2002	CN1374838A Method for stabilizing liquid nutritional products and products so stabilized
10/16/2002	CN1374316A Macrocyclic target specific antisense nucleic acid compound
10/16/2002	CN1374257A Mineralized drinking water and its prepn
10/16/2002	CN1374104A Refined nutritious dahurian rose fruit capsule
10/16/2002	CN1374103A Dahurian rose lozenge
10/16/2002	CN1374097A Production process of orally taken plant insulin prepn
10/16/2002	CN1374094A Orally taken selenium-replenishing prepn
10/16/2002	CN1374093A Diabetes treating Chinese herb medicine
10/16/2002	CN1374091A Diabetes treating medicine and its prepn
10/16/2002	CN1374082A Use of glycogen sulphofoenzyme inhibitor
10/16/2002	CN1374035A Process for producing one or more kinds of dry powder of carotenoid
10/16/2002	CN1092645C Prevention/remedies for complication of diabetes
10/16/2002	CN1092642C Quinoline derivatives as tachykinin NK 3 receptor antagonists
10/16/2002	CN1092641C Preparation for medicine containing substituted pyridyl-dihydroxy-heptenonic acid or its salts
10/16/2002	CN1092517C Method for lowering serum cholesterol levels with 2,6-dialkyl-4-silyl-phenols
10/16/2002	CA2406161A1 2-guanidino-4-arylquinazolines as nhe-3 inhibitors
10/15/2002	US6465687 Thyroid receptor ligands and method
10/15/2002	US6465660 Isoindoloindolone compounds
10/15/2002	US6465524 Therapy for obesity; psychological disorders
10/15/2002	US6465518 2-amino-5-fluoro-6-(1-iminoethylamino)-hept-4-enoic acid, for example; treating or preventing various causes of inflammation
10/15/2002	US6465515 Solid compositions suitable for oral administration containing non-hydroscopic salts of L-carnitine and alkanoyl L-carnitines
10/15/2002	US6465513 Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
10/15/2002	US6465504 Such as 4-(3,5-bis(2-hydroxyphenyl)-(1,2,4)triazol-1-yl)-benzoic acid; treatment of iron overload by mobilizing and eliminating iron deposits; preventing organ damage, in particular of liver, heart and endocrine organs
10/15/2002	US6465501 Azolidines as β3 adrenergic receptor agonists
10/15/2002	US6465500 Indole derivatives as 5-HT1 agonists
10/15/2002	US6465497 Arylthiazolidinedione derivatives
10/15/2002	US6465493 Such as 4-(4-(4-fluorophenyl)-5-(2-pyridyl)-1-hydroxy-1h-imidazol-2-yl)benzonitrile; alk5 mediated diseases such as arthritis, osteoporosis, kidney and renal diseases, conges-tive heart failure, ulcers, diabetic nephropathy
10/15/2002	US6465491 6-phenylpyridyl-2-amine derivatives
10/15/2002	US6465487 Inhibition of membrane-associated viral replication
10/15/2002	US6465478 Analgesics, antiinflammatories, diuretics, anesthetics, neuroprotective agents, antihypertensive or antianxiety agent, appetite control, hearing regulation
10/15/2002	US6465471 Cinnamic acid derivatives
10/15/2002	US6465469 Depression, migraine headaches, panic disorders, post traumatic stress disorder and sleep disorders; side effect reduction
10/15/2002	US6465458 Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor
10/15/2002	US6465451 Hypolipidemic benzothiazepine compounds
10/15/2002	US6465445 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
10/15/2002	US6465444 Protein tyrosine phosphatases(ptp-1b); antidiabetic, antitumor and anorexigenic agents; combination therapy
10/15/2002	US6465426 Acylation
10/15/2002	US6465231 GSK3 polypeptides
10/15/2002	US6465013 Folic acid in solid dosage forms
10/15/2002	US6465011 Formulations comprising lipid-regulating agents
10/15/2002	US6465003 Drug delivery
10/15/2002	US6464959 Protective colloid stabilizer.
10/15/2002	CA2277801C Preparation of particles for inhalation
10/15/2002	CA2091766C Enhancement of glutathione levels with glutamine
10/15/2002	CA2062412C Lowering blood cholesterol levels using water soluble cellulose ethers
10/15/2002	CA2038985C Haloethyl-substituted steroidal enzyme inhibitors
10/10/2002	WO2002079785A2 Phosphoprotein target for insulin and its antagonists
10/10/2002	WO2002079478A2 Modification of organelle metabolism by a composition comprising unc-51-like kinases, roma1, or 2tm polypeptides and uses thereof for the preration of a medicament for the treatment disorders
10/10/2002	WO2002079457A1 Method for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway
10/10/2002	WO2002079448A2 G-protein coupled receptors
10/10/2002	WO2002079441A2 Secreted proteins
10/10/2002	WO2002079266A1 Food product with prolonged energy release
10/10/2002	WO2002079262A1 Composition for enteral nutrition comprising fibres
10/10/2002	WO2002079256A1 Antibody and utilization thereof
10/10/2002	WO2002079249A2 New polynucleotides and polypeptides of the ifn$g(a)-21 gene
10/10/2002	WO2002079238A2 Protein disulfide isomerase and abc transporter homologous proteins involved in the regulation of energy homeostasis
10/10/2002	WO2002079221A2 Sapogenin derivatives, their synthesis and use
10/10/2002	WO2002079204A1 8-thiazolyl[1,2,4]triazolo[1,5-c]pyrimidine derivative
10/10/2002	WO2002079198A1 Pyridazinone aldose reductase inhibitors
10/10/2002	WO2002079197A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/10/2002	WO2002079196A1 Substituted 2-carba-3,5-dicyano-4-aryl-6-aminopyridines and the use of the same as selective ligands of the adenosine receptor
10/10/2002	WO2002079195A1 Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines with adenosine receptor-binding activity and their use as cardiovascular preparations
10/10/2002	WO2002079188A1 Pyrrolidine sulfonamides
10/10/2002	WO2002079162A1 Carboxylic acids
10/10/2002	WO2002079155A1 Pyrrolidine sulfonamides
10/10/2002	WO2002079152A1 Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
10/10/2002	WO2002079146A2 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
10/10/2002	WO2002079139A1 Conjugated unsaturated glyceride mixtures and a method for producing the same
10/10/2002	WO2002078707A1 Pyrrolidine sulfonamides
10/10/2002	WO2002078705A1 Hsp inductor
10/10/2002	WO2002078699A1 Compounds and methods
10/10/2002	WO2002078697A1 Compounds and methods
10/10/2002	WO2002078696A1 Compounds and methods
10/10/2002	WO2002078692A1 Method of treatment
10/10/2002	WO2002078682A2 Estrogen replacement therapy
10/10/2002	WO2002078677A1 Colloidal suspension of nanoparticles based on an amphiphilic copolymer
10/10/2002	WO2002078643A2 Immunomodulation and effect on cell processes relating to serotonin family receptors
10/10/2002	WO2002078641A2 Pyrrolidine sulfonamides
10/10/2002	WO2002078626A2 Therapeutic combinations for cardiovascular and inflammatory indications
10/10/2002	WO2002078625A2 Therapeutic combinations for cardiovascular and inflammatory indications
10/10/2002	WO2002078616A2 Methods for increasing serotonin levels by administering (-)-hydroxycitric acid
10/10/2002	WO2002078469A1 Low glycemic response compositions
10/10/2002	WO2002078458A1 Mixtures of fructose and lactose as a low-calorie bulk sweetener with reduced glycemic index
10/10/2002	WO2002062795A9 Dihydropyrazolopyridine compounds and pharmaceutical use thereof
10/10/2002	WO2002062212A3 A personal condition management system
10/10/2002	WO2002060422A3 Treatment of diabetes mellitus using vardenafil
10/10/2002	WO2002050067A3 Pharmaceutical heterocyclic compounds

1 ... 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 ... 1298